As previously reported, Goldman Sachs analyst Chris Shibutani upgraded AbbVie to Buy from Neutral. Exiting 2023, AbbVie’s delivery of more resilient than expected revenue performance for the Humira franchise in the face of multiple biosimilar entrants and increased confidence in the potential for performance from growth products and signature franchises provides the basis for the view that AbbVie’s current share price reflects underappreciation of the company’s improving growth outlook, the analyst tells investors.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ABBV:
- AbbVie, Genmab present new data for bispecific antibody epcoritamab
- Genmab, AbbVie announce new data from Phase 1/2 EPCORE NHL-1 trial
- After AbbVie agrees to buy Cerevel, analysts weigh in on who may be next
- Cerevel Therapeutics downgraded to Neutral from Overweight at Cantor Fitzgerald
- M & A News: AbbVie (NYSE:ABBV) Doubles Down on Acquisitions, Buys CERE for $8.7B
